GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » EV-to-EBIT

Neuraxis (Neuraxis) EV-to-EBIT : -1.89 (As of May. 27, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Neuraxis's Enterprise Value is $22.67 Mil. Neuraxis's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-11.99 Mil. Therefore, Neuraxis's EV-to-EBIT for today is -1.89.

The historical rank and industry rank for Neuraxis's EV-to-EBIT or its related term are showing as below:

NRXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -17.22   Med: -2.36   Max: -1.67
Current: -1.89

During the past 4 years, the highest EV-to-EBIT of Neuraxis was -1.67. The lowest was -17.22. And the median was -2.36.

NRXS's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 10.295 vs NRXS: -1.89

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Neuraxis's Enterprise Value for the quarter that ended in Mar. 2024 was $22.24 Mil. Neuraxis's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-11.99 Mil. Neuraxis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -53.90%.


Neuraxis EV-to-EBIT Historical Data

The historical data trend for Neuraxis's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis EV-to-EBIT Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - - -1.89

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -5.08 -1.89 -1.86

Competitive Comparison of Neuraxis's EV-to-EBIT

For the Biotechnology subindustry, Neuraxis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuraxis's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Neuraxis's EV-to-EBIT falls into.



Neuraxis EV-to-EBIT Calculation

Neuraxis's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=22.672/-11.987
=-1.89

Neuraxis's current Enterprise Value is $22.67 Mil.
Neuraxis's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuraxis  (AMEX:NRXS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Neuraxis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-11.987/22.240088
=-53.90 %

Neuraxis's Enterprise Value for the quarter that ended in Mar. 2024 was $22.24 Mil.
Neuraxis's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuraxis EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Neuraxis's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuraxis (Neuraxis) Business Description

Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042